- Public Comps
- Lumito
Lumito Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lumito and similar public comparables like Epigenomics, Zicix, Attana, NanoEcho and more.
Lumito Overview
About Lumito
Lumito AB is a Swedish company that specializes in the medical research and development of imaging technology for use in digital pathology. It has developed the next-generation tissue analysis system, based on upconverting nanoparticles (UCNPs). Lumito SCIZYS is a cutting-edge, high-sensitivity system combining labeling and imaging technologies to locate and measure biomarkers in tissue samples. The company holds a broad patent portfolio of three patent families. Lumito’s solution enables quantitative and objective assessment of tissue samples, addressing a multitude of challenges in drug development and academic research.
Founded
2010
HQ

Employees
12
Website
Financials (LTM)
EV
$287K
Valuation Multiples
Start free trialLumito Financials
Lumito reported last 12-month revenue of $51K and negative EBITDA of ($2M).
In the same LTM period, Lumito generated ($2M) in EBITDA losses and had net loss of ($5M).
Lumito P&L
In the most recent fiscal year, Lumito reported revenue of - and EBITDA of ($2M).
Lumito is unprofitable as of last fiscal year, with gross margin of -, EBITDA margin of -, and net margin of -.
Financial data powered by Morningstar, Inc.
Lumito Stock Performance
Lumito has current market cap of $927K, and enterprise value of $287K.
Market Cap Evolution
Lumito's stock price is $0.21.
Lumito share price decreased by 29.5% in the last 30 days, and by 97.8% in the last year.
Lumito has an EPS (earnings per share) of $-1.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $287K | $927K | -0.5% | -29.5% | -34.7% | -97.8% | $-1.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLumito Valuation Multiples
Lumito trades at 5.6x EV/Revenue multiple, and (0.1x) EV/EBITDA.
Lumito Financial Valuation Multiples
As of July 19, 2026, Lumito has market cap of $927K and EV of $287K.
Lumito has a P/E ratio of (0.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lumito Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Lumito Margins & Growth Rates
Lumito grew EBITDA by 9% in the last fiscal year.
Lumito Margins
Lumito Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Lumito Operational KPIs
Lumito's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Lumito Competitors
Lumito competitors include Epigenomics, Zicix, Attana, NanoEcho, Strata Skin Sciences, ViewRay, Level Bio, Brainscan, Prostatype Genomics and Elite Diagnostic.
Most Lumito public comparables operate across Medical Imaging & Diagnostics and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 491.9x | - | (37.6x) | - | |||
| - | - | - | - | |||
| 5.8x | - | (1.7x) | - | |||
| 28.9x | - | (1.0x) | - | |||
| 0.3x | - | 47.2x | - | |||
| 0.0x | - | (0.0x) | - | |||
| 0.6x | - | (15.4x) | - | |||
| 43.2x | - | (2.8x) | - | |||
This data is available for Pro users. Sign up to see all Lumito competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lumito
| When was Lumito founded? | Lumito was founded in 2010. |
| Where is Lumito headquartered? | Lumito is headquartered in Sweden. |
| How many employees does Lumito have? | As of today, Lumito has over 12 employees. |
| Is Lumito publicly listed? | Yes, Lumito is a public company listed on Nasdaq Global Market. |
| What is the stock symbol of Lumito? | Lumito trades under LUMITO ticker. |
| When did Lumito go public? | Lumito went public in 2018. |
| Who are competitors of Lumito? | Lumito main competitors include Epigenomics, Zicix, Attana, NanoEcho, Strata Skin Sciences, ViewRay, Level Bio, Brainscan, Prostatype Genomics, Elite Diagnostic. |
| What is the current market cap of Lumito? | Lumito's current market cap is $927K. |
| What is the current revenue of Lumito? | Lumito's last 12 months revenue is $51K. |
| What is the current revenue growth of Lumito? | Lumito revenue growth (NTM/LTM) is 960%. |
| What is the current EV/Revenue multiple of Lumito? | Current revenue multiple of Lumito is 5.6x. |
| Is Lumito profitable? | No, Lumito is not profitable. |
| What is the current EBITDA of Lumito? | Lumito has negative EBITDA and is not profitable. |
| What is Lumito's EBITDA margin? | Lumito's last 12 months EBITDA margin is (4872%). |
| What is the current EV/EBITDA multiple of Lumito? | Current EBITDA multiple of Lumito is (0.1x). |
| How many companies Lumito has acquired to date? | Lumito hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Lumito has invested to date? | Lumito hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Lumito
Lists including Lumito
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




